FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the
regulation of development and tissue repair. However, alterations in FGFRs 1–4, such as …

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …

Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-
FGFR inhibitor. Patients and Methods: Patients age≥ 18 years with advanced solid tumors …

The success of targeted or immune therapies is often hampered by the emergence of
resistance and/or clinical benefit in only a subset of patients. We hypothesized that …

Purpose: To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of
Debio 1347, a selective FGFR inhibitor. Patients and Methods: This was a first-in-human …

Background S1400D is a biomarker-driven therapeutic substudy of Lung-MAP evaluating
the fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with FGF …

Aberrant activation in fibroblast growth factor signaling has been implicated in the
development of various cancers, including squamous cell lung cancer, squamous cell head …

Introduction Genomic profiling informs selection of matched targeted therapies as part of
routine clinical care in NSCLC. Tissue biopsy is the criterion standard; however, genomic …

Introduction There is substantial evidence for the oncogenic effects of fibroblast growth factor
receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this …

Background Small cell lung cancer (SCLC) is one of the deadliest malignancies and
accounts for nearly 15% of lung cancers. Previous study had revealed the genomic …